Compare VENUS REMEDIES with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES STERLING BIOTECH VENUS REMEDIES/
STERLING BIOTECH
 
P/E (TTM) x -1.1 -0.4 - View Chart
P/BV x 0.1 0.0 546.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   STERLING BIOTECH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
STERLING BIOTECH
Dec-13
VENUS REMEDIES/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs12611 1,199.0%   
Low Rs613 1,797.1%   
Sales per share (Unadj.) Rs301.826.8 1,125.8%  
Earnings per share (Unadj.) Rs-24.9-15.0 166.3%  
Cash flow per share (Unadj.) Rs2.5-5.5 -46.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.354.9 534.4%  
Shares outstanding (eoy) m12.34267.87 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 119.5%   
Avg P/E ratio x-3.8-0.5 809.1%  
P/CF ratio (eoy) x36.7-1.3 -2,888.2%  
Price / Book Value ratio x0.30.1 251.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1541,862 62.0%   
No. of employees `0000.91.4 68.3%   
Total wages/salary Rs m393547 71.9%   
Avg. sales/employee Rs Th4,026.15,303.3 75.9%   
Avg. wages/employee Rs Th425.0403.8 105.2%   
Avg. net profit/employee Rs Th-331.8-2,959.0 11.2%   
INCOME DATA
Net Sales Rs m3,7247,181 51.9%  
Other income Rs m2343 52.8%   
Total revenues Rs m3,7477,223 51.9%   
Gross profit Rs m395947 41.7%  
Depreciation Rs m3382,543 13.3%   
Interest Rs m3544,377 8.1%   
Profit before tax Rs m-275-5,931 4.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32-1,924 -1.6%   
Profit after tax Rs m-307-4,007 7.7%  
Gross profit margin %10.613.2 80.4%  
Effective tax rate %-11.532.4 -35.4%   
Net profit margin %-8.2-55.8 14.8%  
BALANCE SHEET DATA
Current assets Rs m2,63814,335 18.4%   
Current liabilities Rs m2,30549,809 4.6%   
Net working cap to sales %8.9-494.0 -1.8%  
Current ratio x1.10.3 397.7%  
Inventory Days Days135403 33.6%  
Debtors Days Days46171 27.1%  
Net fixed assets Rs m4,87155,432 8.8%   
Share capital Rs m123268 46.1%   
"Free" reserves Rs m3,49613,935 25.1%   
Net worth Rs m3,61914,701 24.6%   
Long term debt Rs m1,3749,478 14.5%   
Total assets Rs m7,50973,988 10.1%  
Interest coverage x0.2-0.4 -62.8%   
Debt to equity ratio x0.40.6 58.9%  
Sales to assets ratio x0.50.1 511.1%   
Return on assets %0.60.5 126.0%  
Return on equity %-8.5-27.3 31.1%  
Return on capital %1.6-6.4 -24.6%  
Exports to sales %025.9 0.0%   
Imports to sales %13.90.2 8,163.7%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs m51712 4,233.9%   
Fx inflow Rs m01,860 0.0%   
Fx outflow Rs m51725 2,075.1%   
Net fx Rs m-5171,835 -28.1%   
CASH FLOW
From Operations Rs m5141,719 29.9%  
From Investments Rs m-123-3,148 3.9%  
From Financial Activity Rs m-3871,426 -27.1%  
Net Cashflow Rs m4-3 -123.5%  

Share Holding

Indian Promoters % 32.9 33.9 96.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 9.9 5.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 66.4 39.3 169.0%  
Shareholders   20,121 21,482 93.7%  
Pledged promoter(s) holding % 36.4 55.9 65.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 15, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS